The conflation of "compounded" with "counterfeit" is one of the most persistent and damaging misunderstandings in the GLP-1 conversation. It's promoted — sometimes deliberately — by brand-name manufacturers who benefit from the confusion, and repeated by media outlets that don't understand pharmaceutical regulation.
Let's be clear: compounded medications are a legal, regulated, and longstanding category of pharmaceutical practice in the United States. They are not counterfeits. They are not "knockoffs." They occupy a specific regulatory category that exists because the healthcare system needs them.
What Compounding Actually Is
Pharmaceutical compounding is the practice of creating customized medications to meet individual patient needs. It has existed for as long as pharmacy itself — historically, all medications were compounded. Today, compounding serves patients who need dosage forms not commercially available (liquid instead of tablet), allergen-free formulations, pediatric doses, or — critically for the GLP-1 market — access to medications during shortages or at affordable prices.
Compounding is regulated under two federal frameworks: Section 503A of the Federal Food, Drug, and Cosmetic Act (covering traditional pharmacies filling patient-specific prescriptions under state board oversight) and Section 503B (covering outsourcing facilities that operate under FDA registration and cGMP requirements, producing larger batches without patient-specific prescriptions).
The Legitimate Concerns
Compounding is legal and regulated. It is also less rigorous than FDA approval — by design. The legitimate concerns include potency variability between batches (less standardized than brand-name manufacturing), sterility risks (compounding errors have caused contamination events historically), and lack of bioequivalence data (compounded products haven't proven they deliver the same blood levels as approved versions).
These concerns are real. They're also manageable — which is why the distinction between 503A and 503B matters. 503B outsourcing facilities operate under FDA oversight, follow cGMP, and are subject to FDA inspection. 503A pharmacies are state-regulated, with standards varying significantly by state. The quality gap between a well-run 503B facility and a poorly regulated 503A pharmacy is substantial.
"Compounded = counterfeit" is not a fact. It's a talking point. Compounded GLP-1 medications are legal, prescribed by licensed physicians, prepared by regulated pharmacies, and used by millions of patients. They are not FDA-approved as finished products — that's a real distinction worth understanding — but "not FDA-approved" and "counterfeit" are entirely different categories. Conflating them serves the financial interests of brand-name manufacturers, not the informational needs of patients.
Ask your provider: Is the pharmacy 503A or 503B? Is it FDA-registered (503B) or state-licensed (503A)? Is it LegitScript certified? Can they provide a Certificate of Analysis for the specific batch? If a provider won't answer these questions, that's a red flag — not about compounding as a category, but about that specific provider's sourcing.
Sema $99/mo, tirz $133/mo at any dose. LegitScript certified, 503A+503B pharmacies. Free consult, free shipping, no membership. Also NAD+ and sermorelin. Code x7X72r saves $25.
$99/month at every dose — verified flat. LegitScript, FSA/HSA. No price jumps at maintenance.
Compounded sema $125/mo, tirz $199/mo. Brand-name Mounjaro/Zepbound available. Code Bilt35 = 35% off first order.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Individual results vary.